eCommons@AKU
Department of Biological & Biomedical Sciences

Medical College, Pakistan

January 2016

Anti mullerian hormone: Ovarian response
indicator in young patients receiving long GnRH
agonist protocol for ovarian stimulation
Zehra Jamil
Aga Khan University, zehra.jamil@aku.edu

Syeda Sadia Fatima
Aga Khan University, sadia.fatima@aku.edu

Rehana Rehman
Aga Khan University, rehana.rehman@aku.edu

Faiza Alam
Aga Khan University

Sara Arif
Civil Hospital, Karachi, Pakistan

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs
Part of the Biochemistry Commons
Recommended Citation
Jamil, Z., Fatima, S. S., Rehman, R., Alam, F., Arif, S. (2016). Anti mullerian hormone: Ovarian response indicator in young patients
receiving long GnRH agonist protocol for ovarian stimulation. Pakistan Journal of Medical Sciences, 32(4), 944-949.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/391

Open Access
Original Article

Anti Mullerian Hormone: Ovarian response indicator in
young patients receiving Long GnRH Agonist Protocol
for Ovarian Stimulation
Zehra Jamil1, Syeda Sadia Fatima2,
Rehana Rehman3, Faiza Alam4, Sara Arif

5

ABSTRACT
Objective: Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance.
We explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in
younger and older infertile population.
Methods: This retrospective analysis compiled data of 166 females, receiving ICSI treatment from June
2014 to March 2015. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were
measured as good (5 to 19 oocytes) and bad responders.
Results: Higher discriminatory power of AMH (AUROC; 0.771; p < 0.05) was seen in comparison to FSH
(0.692; p < 0.05) and AFC (0.690; p < 0.01). AMH reported strongest association with oocyte retrieved (odds
ratio of 15.06). Subgroup analysis reported 68.6 % risk of bad response with AMH levels of less than 1.37ng/
ml. This association was observed more significant in young infertile patients <35 year of age (r=0.245;
p=0.012) versus older population >35 year (r=0.169; p>0.05).
Conclusion: Our study reaffirms that serum AMH correlates well with oocytes retrieved, particularly
in females younger than 35 years. We suggest incorporation of AMH in baseline assessment of infertile
females, who are falsely advised to postpone interventions based on their age and normal FSH levels.
KEY WORDS: Anti Mullerian Hormone, Assisted Reproductive Technology, Ovarian stimulation, Ovarian
reserve.
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INTRODUCTION
Fertility of females resides in the pool of
primordial follicles, they are born with. Amongst
these, 30 to 50 follicles are recruited with each
menstrual cycle leading to decline in fertility after
the age of 30 years.1 In cases of infertility, evaluation
of ovarian reserve (OR) is essential to optimize
protocol for assisted reproductive technique (ART)
and prediction of response to counsel the couple.2
The likelihood of successful ovarian response is
usually assessed on age; most dependable variable
affecting results of treatment. However, even
within comparable ages, wide variability has been
reported,3 concluding age as a weak reflector of
ovarian pool. Thus other markers such as Follicle
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stimulating hormone (FSH), luteinizing hormone
(LH), Inhibin, Estradiol (E2), ovarian volumes and
antral follicle count (AFC) have been deployed to
predict the response.4
A rise in FSH levels is most widely recognized
hallmark of reduction in the OR.5 It may not be
the best option as it suffers inter and intra cyclic
fluctuations.6 FSH production is further deranged
in patients receiving oral contraceptive pills, in
polycystic ovarian syndrome (PCOS) and pituitary
tumors.7 Similarly, AFC is assessed for estimation
of dosage and in predicting response to stimulation
but operators’ variability, mechanical consistency
and previous history of ovarian surgery are its main
limitations.
Anti Mullerian hormone (AMH) is recently
considered as a unique OR marker, solely
secreted by granulosa cells and accurately reflects
primordial follicle.8 It is a glycoprotein dimer
belonging to TGF-β family and has potential role
in the maintenance of OR.9,10 Drop in serum AMH
reliably indicates decline in ovarian function.
Hence, it is now being used to assess ovarian
injury induced by chemotherapy, radiation therapy
or ovarian surgery.11 It correlates well with the
number of oocytes retrieved after stimulation and
reflects excessive follicular growth in women with
ovarian hyper stimulation syndrome (OHSS) and
PCOS.12,13 These oocytes retrieved after stimulation,
reflects availability of embryos for transfer and
hence an optimum response to Long GnRH agonist
protocol is said to achieve by retrieval of at least five
oocytes.14
Therefore, this study aimed to assess reliability
of various markers (like FSH, AFC and AMH) in
predicting response to intra-cytoplasmic sperm
injection (ICSI). Our results propose that regarding
number of oocytes retrieved, AMH is a better

predictor in comparison to age, BMI, AFC and FSH,
particularly in younger infertile population (20 to
35 years).
METHODS
In this retrospective cross-sectional analysis,
data of 166 infertile females was collected from
Australian Concept Infertility Medical Centre
(ACMIC). Females booked for the first ICSI
treatment from June 2014 to March 2015, aged 20 to
42 year, with regular menstrual cycles, no endocrine
disorders or prior ovarian surgery, were included
while PCOS were excluded from study. Ethical
clearance was obtained from ACMIC. Written
consent was waived by Institutional review board
as retrospective design could not alter the clinical
decision made during ICSI treatment. Furthermore,
patients’ records were anonymized prior to analysis
to maintain confidentiality. Serum samples were
collected on days 2–3 of menstrual cycles one
month prior to ICSI treatment. Supernatant fluid
was used for the assays maintained at temperature
from 2-8 ºC.
AMH was measured using AMH Gen 11 Elisa
reagent kit (Beckman coulter, ref a79765). FSH
and LH were measured using Elecsys reagent
kit following the manufacturer protocol. AFC
assessment was carried out on day 3, using an
Aloka SSD-1000 (Japan) with a 5 MHz transvaginal
probe. Follicles measuring <10 mm in diameter
were counted in both ovaries to determine the
cohort with an inter observer CV <5%.
1 mg of subcutaneous Buserelin Acetate
(Suprefact) was initiated on day 21 to achieve
adequate ovarian suppression, followed by
recombinant FSH (Gonal-f) or hMG (Menogon).
hCG (Ovitrelle, 250 μg, Merck Serono) was
administered on an adequate E2 response and two

Table-I: Descriptive statistics of whole cohort and according to responder category.
Variables

Whole Study Population
n =166

Good Responder (5-19 oocyte count)

		

Mean ± SD

Age (year)
BMI (kg/m2)
FSH (IU/L)
LH (IU/L)
AMH (ng/ml)
AFC
Estradiol (pg/ml)

31.7 ± 5.4
28.70 ± 5.4
6.9 ± 3.2
6.5 ± 1.7
2.3 ± 0.7
10.6 ± 5.1
48.0 ± 6.78

33.6 ± 6.03
29.3 ± 5.41
8.5 ± 4.9
6.9 ± 1.057
1.6 ± 1.3
9.3 ± 4.3
46.95 ± 6.3

Bad Responder (<5, >19 oocytes)

n =90

n = 76
35.6 ± 6.0
29.8± 5.3
10.2 ± 5.7*
7.4 ± 1.4
1.4 ± 0.5*
7.9 ± 2.6 *
45.0 ± 7.3

Data expressed as Mean ± S.D. Mann Whitney U test was used to compare the difference between groups.
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Table-II: Biophysical and Biochemical Variables on the basis of AMH, FSH and Age Category.
Age
35-42 year
n = 60

20-35 year
n =106

AMH

FSH

Normal >1.37ng/ml Low <1.37ng/ml
n =14
n = 152

Normal < 11 IU/L High >11 IU/L
n =106
n = 60

Mean ± SD
Age (year)
BMI (kg/m2)
FSH (IU/L)
LH (IU/L)
AMH (ng/ml)
AFC
Good Responder%
Bad Responder %

40.2 ± 3.5
30.1 ± 5.2
9.1 ± 5.3
7.3 ± 2.5
1.5 ± 0.8
8.4 ± 2.9
36.6
63.3

29.9±3.4*
28.8±5.5
8.1 ± 4.6
6.8 ± 1.1
2.0 ± 0.3*
9.8 ± 4.8
58.5
41.5

33 ± 8.9
33.4 ± 3.3
5.9 ± 3.3
4.3 ± 2.5
2.8 ± 1.1
8.0 ± 1.9
85.7
14.2

33.6 ± 5.7
28.9 ± 5.4*
8.8 ± 4.5
7.2 ± 1.5
0.7 ± 0.3*
9.4 ± 4.4
47.4
52.6

32.3 ±5.7
28.9 ± 5.1
6.1± 1.9
4.5 ± 2.4
2.2 ± 0.4
8.6 ± 4.6
62.2
37.7

36 ± 6.0
30 ± 5.6
13 ± 5.5*
11.3 ± 4.4*
1.2 ± 0.5*
9.7 ± 4.0*
30.0
70.0

Data expressed as Mean ± S.D. and frequency and percentage wherever applicable.
Mann Whitney U test was used to compare the difference between groups. *p<0.05 considered significant.

or more follicles measuring ≥18 mm. Oocytes were
retrieved trans-vaginally and sperms were injected.
Embryos were transferred into uterus after 72 hours
of insemination. Luteal phase support was given by
Pregnyl 1500 IU. Clinical pregnancy was confirmed
by sonographic evidence of an intrauterine
gestational sac.
Main outcome was measured as good
responders having at least 5 to 19 oocytes
retrieved while bad responders had either less
than 5 or more than 19 oocytes retrieved. Positive
pregnancies were not considered as the outcome
due to limited size of sample and inclusion of
cases with male infertility.
Data was analyzed by SPSS version 19 and
comparison of variables was done by Mann
Whitney U test. Logistic regression determined the
predictive value for ovarian response while AUROC
analysis was used to see the predictive accuracy of
FSH and AMH. Spearman bivariate correlation was
applied between AMH and FSH. P value of <0.05
was considered significant.
RESULTS
The mean BMI, FSH and AMH levels of one
hundred and sixty-six infertile females recruited

in this study is summarized in Table-I. While
grouping them according to oocytes retrieved,
both AMH and AFC were significantly low in bad
responders (p < 0.05) whereas FSH was raised
(p <0.05).
Table-II compares the groups according to
AMH cut off, FSH and age. One hundred fifty
two females reported low AMH and out of these,
only 47.5% responded well while in higher AMH
category, 85.7% females had a good response. In
these groups, significant difference in AMH was
observed (p<0.01) whereas LH, FSH and AFC had
insignificant difference. On FSH stratification,
significant difference in the levels of LH, AMH
and AFC (p <0.05) was observed. Good response
was reported by 62.2% of normal while 30.0%
of raised FSH group. In age segregated groups,
insignificant variance was seen for AMH, LH and
FSH.
Next, on binary logistic regression, unadjusted
model reported that females with low AMH were
6.66 times more likely to have a poor response than
raised FSH (3.66 times). After adjusting for age and
BMI, AMH gave even stronger positive significant
association with the responder group [OR 15.06
(2.83- 80.01)] versus FSH [OR 4.12 (1.12-9.86)]
(Table-III).

Table-III: Logistic Regression Analysis for FSH, AMH and AFC.
Variables

Unadjusted
OR

Adjusted for Age and BMI

95% C.I		

OR

95% C.I

		

Lower

Upper		

Lower

Upper

FSH
AMH
AFC

1.85
1.44
0.70

7.24
30.80
0.89

1.72
2.83
0.72

9.86
80.01
0.90

3.66*
6.66*
0.79*
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4.12*
15.06*
0.81*
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Fig.1: Correlation of Serum AMH (A) and Serum FSH (B) with the number of oocyte retrieved after stimulation.
Patients grouped according to ages between 20 to 35 year and 35 to 42 year.

Fig.1 presents correlation of AMH and FSH with
oocytes retrieved in various age groups. AMH
depicted stronger positive association in patients
<35 year of age (r=0.245; p=0.012) versus patients
>35 year (r=0.169; p>0.05). FSH depicted negative
correlation that was likewise higher in patients
<35 year of age (r=-0.415; p<0.001). In addition,
significant negative correlation with bad responders
was observed between the oocyte retrieval and
AMH (r = -0.468, p <0.001), whereas significant
positive correlation was seen with FSH (r = 0.332, p
< 0.001).
Later, ROC analysis observed the discriminatory
power of AMH along with FSH and AFC in two
responder groups (Table-III). The AUROC for AMH
was highest (0.771; p < 0.05) in terms of accurately
discriminate between good and bad responders.
FSH and AFC had a lower discriminatory power
(0.692 and 0.690 respectively; p < 0.05). The AMH
cut-off levels were calculated by the online software
MedCalc15 for poor ovarian response. A value of
1.37ng/ml was calculated, with a specificity of 75%
and a sensitivity of 90% to exhibit higher ability to
discriminate between good and bad responders
in all the groups. Serum AMH levels of less than

1.37ng/ml was associated with bad response while
that of higher than 1.37ng/ml correlated better
ovarian reserve.
DISCUSSION
Young females are often advised to postpone
infertility treatment based on their age and
FSH levels. Hence, we explored strength of
biomarkers including recently acclaimed AMH in
discriminating between good and bad responder.
Furthermore, we analyzed ovarian response in
sub-groups segregated on the bases of age, FSH
levels and AMH cut-off values calculated in our
population.
In this study, we report significant correlation of
oocytes retrieved with FSH, AMH and AFC while
no association with age, BMI or LH. In comparison
to FSH and AFC, AMH had a superior role as a solo
marker of response. The AUROC for AMH was
significantly higher than FSH and AFC (p <0.05).
Our results revealed that 85.7% patients with normal
AMH retrieved more than 5 oocytes. Furthermore,
in unadjusted models of binary logistic regression,
low AMH showed highest ability to identify bad
responder as compared to raised FSH or AFC (6.66
Pak J Med Sci 2016 Vol. 32 No. 4
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times and 3.66 times respectively). Undoubtedly,
AFC assessment is substantial to monitor infertility
treatment however, operator’s variability is its
limitation.16 As blood tests have marked advantages
over ultrasound for primary care physicians, AMH
has a greater efficiency over AFC, especially in
setups where high class technology is not feasible.
While comparing AMH with the most commonly
used marker FSH, segregation on the basis of
FSH showed significant inverse correlation with
AMH (Table-II). Therefore, we suggest AMH as
its substitute in cases of deranged FSH production
as discussed earlier. Being an “acyclic” marker,
AMH assessment is considered reliable anytime
throughout menstrual cycle17 although few studies
do report converse findings.18
To further reinforce our results, AMH cut-off
value for our population was calculated as 1.37ng/
ml with the strength of 75% specificity and 90%
sensitivity to correctly predict the response. We
found that 87% patients having more than 1.37ng/
ml AMH reported higher oocyte retrieval. Similarly,
mean AMH of patients who conceived on ICSI was
observed as 1.78 ± 0.95ng/ml. However, due to the
limitation of sample size and inclusion of couples
with male infertility, we cannot debate on wider
role of AMH in predicting pregnancy outcomes.
Various cut-off are reported across the globe. An
Indian study has reported serum AMH levels of
less than 1.4ng/ml as suggestive of poor ovarian
response to stimulation.19 Here, it is important
to emphasize that these cut-offs need to be used
with caution as in our study we witnessed one
patient reporting good response even with serum
AMH of 0.6ng/ml. European study quoted AMH
levels of as low as 0.8 µg/l as sufficient to reflect
healthy ovarian response.20 This might be explained
as although low AMH reflects decline in OR, but
even few oocyte of good quality may still respond
to gonadotropin stimulation. Thus, we advocate its
capability in counselling infertile couples, selecting
treatment protocol and tentatively predicting
chances of pregnancy. 21
Next, we assessed AMH as a predictor of oocyte
retrieval in two different groups based on age.
In our study there was a stronger correlation in
patients younger than 35 years (p<0.001, Fig.1 A
and B). This further supports role of AMH to predict
ART outcome in younger population that might
be misjudged due to early age and a normal FSH.
Studies do report that in population of similar age
group, wide variations of OR have been testified in
948 Pak J Med Sci 2016 Vol. 32 No. 4
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individuals.3 This explains the variation observed
in AMH levels but its assessment along with other
baseline investigations seems to be of additional
value in screening young infertile patients with
a decreased OR. Contrary to this, David H et al.
reported significant correlation of AMH and oocyte
retrieval in older infertile women.22 This difference
could possibly be due to population stratification or
selection criteria. Our study further reports similar
results between FSH levels and oocyte retrieval as
it was likewise found to correlate better in younger
population (p<0.001, Fig.1 A and B). On the other
hand, AFC showed higher correlation in the older
group. Our results reported insignificant difference
in AMH of patients with varied BMI, thus
suggesting that it reflects true ovarian response
irrespective of the patient’s BMI as also supported
by earlier work.23
In conclusion, we support the role of AMH in
reflecting the number of oocytes collected for
successful ART. For the first time, we are reporting
AMH levels in Pakistani infertile population
and predict a cut-off value of 1.37ng/ml that
discriminate good and bad responders. We strongly
suggest incorporation of AMH evaluation in
baseline assessment of ovarian reserve, especially
in younger infertile patients as timely IVF treatment
can improve the pregnancy outcomes in these
populations. As our sample size was limited and
localized, further longitudinal studies are required
to reassess the cut-off values. Furthermore, studies
focusing on association of serum AMH with viable
pregnancy outcomes will increase the support for
AMH as a predictive marker of live births in ART
clinics.
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